CD8A and non-small cell lung carcinoma: In this study, we have demonstrated that CDK7 inhibition in NSCLC cells downregulated PD-L1 expression via suppressing the p38α-MYC axis and boosts antitumor immunity of antiPD-1 therapy in vivo by recruiting infiltrating CD8+ T cells.